Target intelligence / Profile preview

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3Kα) RAS-binding domain Cys242 (PI3Kα RBD Cys242)

Target
PI3Kα RBD Cys242
Molecular classification
Enzyme, Lipid kinase, Phosphoinositide 3-kinase (PI3K) family, Class IA PI3K
01

Overview

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3Kα), encoded by the PIK3CA gene, is a critical lipid kinase in the PI3K/AKT/mTOR signaling pathway, regulating cell growth, survival, and metabolism [1.3.1, 1.4.1]. The RAS-binding domain (RBD) of PI3Kα facilitates its recruitment and activation by RAS GTPases, a process frequently dysregulated in various cancers [1.1.2, 1.3.5]. Cys242 is a unique, isoform-exclusive cysteine residue located within the RBD of PI3Kα [1.1.1, 1.3.4]. Targeting Cys242 with covalent small-molecule inhibitors, such as BBO-10203 and VVD-699, selectively disrupts the protein-protein interaction between RAS and PI3Kα [1.2.3, 1.3.1]. This strategy aims to inhibit oncogenic signaling in RAS-mutant or HER2-overexpressing tumors while sparing the insulin-mediated PI3K signaling required for glucose homeostasis [1.1.2, 1.3.3]. By avoiding the inhibition of the kinase's catalytic site, these Cys242-targeted agents potentially mitigate the dose-limiting hyperglycemia associated with traditional ATP-competitive PI3Kα inhibitors [1.3.1, 1.4.1].

Other names
p110α Cys242PIK3CA Cys242PI3Kα RBD C242RAS-binding domain of PI3KαCysteine 242 of p110α
02

Mechanism of action

Covalent inhibition of Cys242 in the RAS-binding domain to disrupt the RAS-PI3Kα protein-protein interaction.

03

Biological functions

Signal transductionCell proliferationCell survivalMetabolismRAS-mediated PI3K activation
04

Disease associations

CancerBreast cancerColorectal cancerNon-small cell lung cancerSolid tumor
05

Safety considerations

Selectivity for Cys242 over other cellular cysteinesPotential for bypass resistance mechanismsTherapeutic window optimization
06

Interacting drugs

BBO-10203

5 more in the full profile.

07

Biomarkers

PIK3CA mutationRAS mutation (KRAS, HRAS, NRAS)HER2 amplificationpAKT (S473) phosphorylation

Beyond the preview

Go deeper on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3Kα) RAS-binding domain Cys242 (PI3Kα RBD Cys242).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3Kα) RAS-binding domain Cys242 (PI3Kα RBD Cys242).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call